STING1 and hepatocellular carcinoma: Notable trends include the dominance of HCC trials (reflecting its global burden and the synergy between local and systemic therapy), the prominence of cryoablation in breast and prostate cancer, and the exploration of novel adjuvants (TLR agonists, STING agonists) in early-phase studies.